Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Magnani

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Thrombosis and Haemostasis|October 18, 1993
Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)H N Magnani
Thrombosis Research|November 21, 2009
A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysisH N Magnani
Thrombosis Research|August 7, 2009
An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran)H N Magnani
Biochimica Et Biophysica Acta|December 20, 1976
The influence of LP-X and other lipoproteins associated with hepatic dysfunction on the activity of lecithin:cholesterol acyltransferaseH N Magnani
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 4, 2021
Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 InfectionHarry N Magnani
BMJ (Clinical Research Ed.)|July 17, 1993
Management of heparin induced thrombocytopeniaH N Magnani
Clinical Chemistry|February 1, 1981
Existence of alkaline phosphatase-lipoprotein X complex questionedH N Magnani
Lancet (London, England)|November 21, 1981
Partial ileal bypass in familial hypercholesterolaemiaH N Magnani
Thrombosis and Haemostasis|May 30, 2006
Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004Harry N Magnani, Alex Gallus
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 1, 1972
A method for the quantitative determination of the abnormal lipoprotein (LP X) of obstructive jaundiceH N Magnani, P Alaupović
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Thrombosis and Haemostasis|October 18, 1993
Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)H N Magnani
Thrombosis Research|November 21, 2009
A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysisH N Magnani
Thrombosis Research|August 7, 2009
An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran)H N Magnani
Biochimica Et Biophysica Acta|December 20, 1976
The influence of LP-X and other lipoproteins associated with hepatic dysfunction on the activity of lecithin:cholesterol acyltransferaseH N Magnani
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 4, 2021
Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 InfectionHarry N Magnani
BMJ (Clinical Research Ed.)|July 17, 1993
Management of heparin induced thrombocytopeniaH N Magnani
Clinical Chemistry|February 1, 1981
Existence of alkaline phosphatase-lipoprotein X complex questionedH N Magnani
Lancet (London, England)|November 21, 1981
Partial ileal bypass in familial hypercholesterolaemiaH N Magnani
Thrombosis and Haemostasis|May 30, 2006
Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004Harry N Magnani, Alex Gallus
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 1, 1972
A method for the quantitative determination of the abnormal lipoprotein (LP X) of obstructive jaundiceH N Magnani, P Alaupović
Pageof 6